These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34535199)

  • 1. Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease.
    ; ; ; ; ;
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Sept 15; 23(9):867-876. PubMed ID: 34535199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.
    ; ; ; ; ; ; ; ;
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Mar; 24(3):225-231. PubMed ID: 35351250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pediatric expert consensus on the application of aspirin in Kawasaki disease].
    ; ; ; ; ; ; ; ; ;
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun; 24(6):597-603. PubMed ID: 35652428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)].
    ; ; ; ; ; ; ; ; ;
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Dec; 25(12):1198-1210. PubMed ID: 38112136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience of IVIG Treatment in an Overweight 14-year-old Child With Kawasaki Disease: A Case Report.
    Shi H; Qiu JL; Xu Y; Yang LL
    J Pediatr Health Care; 2024; 38(4):624-628. PubMed ID: 37897455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
    Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA;
    Pediatrics; 2004 Dec; 114(6):1708-33. PubMed ID: 15574639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
    Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA; ; ; ;
    Circulation; 2004 Oct; 110(17):2747-71. PubMed ID: 15505111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q; Gong FQ; Shang SQ; Hu J
    Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):501.e1-11; quiz 511-2. PubMed ID: 24034379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China.
    Huang H; Jiang J; Shi X; Qin J; Dong J; Xu L; Huang C; Liu Y; Zheng Y; Hou M; Shen Q; Zeng B; Qian G; Yang F; Lv H
    Ann Med; 2022 Dec; 54(1):442-453. PubMed ID: 35099338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
    Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

  • 17. A 10-year cross-sectional retrospective study on Kawasaki disease in Iranian children: incidence, clinical manifestations, complications, and treatment patterns.
    Sadeghi P; Izadi A; Mojtahedi SY; Khedmat L; Jafari M; Afshin A; Yarahmadi P; Hosseinali Beigi E
    BMC Infect Dis; 2021 Apr; 21(1):368. PubMed ID: 33874899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS; Raskin A; Gudausky TM; Kirkpatrick E
    Am J Ther; 2016; 23(6):e1293-e1299. PubMed ID: 25611359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.